This significantly inhibits the progression and migration of cancer, especially in cases of HER2+ breast cancer (Herceptin),96 metastatic colorectal cancer (Eribitux), and advanced head and neck cancer (Erbitux).97 Two additional HER-2-targeting monoclonal antibodies, margetuximab (Margenza) and pertuzumab (Perjeta), have been approved for the treatment of metastatic HER-2+ breast cancer, either in combination with or as an alternative to Herceptin.98,99. This evidence concerns the gene ERBB2 and breast carcinoma.